Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
Canopy Growth Corp
SIC 2833 · Medicinal Chemicals & Botanical Products
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Canopy Growth Corp
SIC 2833 · Medicinal Chemicals & Botanical Products
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Canopy Growth Corp
SIC 2833 · Medicinal Chemicals & Botanical Products
Support
about
terms
$
CGC
Canopy Growth Corp
CIK:
0001737927
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - CAD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]
Revenue
$ 100,364
$ 88,748
Excise taxes
19,199
16,614
Net revenue
81,165
72,134
Cost of goods sold
58,927
54,096
Gross margin
22,238
18,038
Operating expenses
Selling, general and administrative expenses
40,223
38,108
Share-based compensation
1,359
(99)
Loss on asset impairment and restructuring
2,766
2,653
Total operating expenses
44,348
40,662
Operating loss
(22,110)
(22,624)
Other income (expense), net
7,402
(21,946)
Loss before income taxes
(14,708)
(44,570)
Income tax recovery (expense)
129
(291)
Net loss
$ (14,579)
$ (44,861)
Basic and diluted loss per share
Basic loss per share
$ (0.03)
$ (0.24)
Diluted loss per share
$ (0.03)
$ (0.24)
Basic weighted average common shares outstanding
422,264,025
188,321,555
Diluted weighted average common shares outstanding
422,264,025
188,321,555
Other comprehensive income (loss), net of income tax
Foreign currency translation
$ 4,830
$ 6,713
Total other comprehensive income (loss), net of income tax
4,830
6,713
Comprehensive loss
$ (9,749)
$ (38,148)
v3.26.1
Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - CAD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:
Net loss
$ (14,579)
$ (44,861)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment
5,351
4,753
Amortization of intangible assets
4,683
4,917
Share-based compensation
1,359
(99)
Loss on asset impairment and restructuring
167
109
Income tax (recovery) expense
(129)
291
Non-cash fair value adjustments and charges related to settlement of long-term debt
(16,867)
13,383
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable
(6,130)
2,915
Inventory
3,454
2,838
Prepaid expenses and other assets
(1,541)
(2,668)
Accounts payable and accrued liabilities
(2,417)
5,184
Other, including non-cash foreign currency
1,638
2,901
Net cash used in operating activities
(25,011)
(10,337)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment
(737)
(1,306)
Purchases of intangible assets
0
(183)
Proceeds on sale of property, plant and equipment
0
5
Redemption of short-term investments
0
779
Net cash used in investing activities
(737)
(705)
Cash flows from financing activities:
Proceeds from issuance of common shares and warrants
0
38,261
Payment of debt issue costs
(647)
0
Repayment of long-term debt
0
(916)
Other financing activities
(6,821)
(11,885)
Net cash (used) provided by financing activities
(7,468)
25,460
Effect of exchange rate changes on cash and cash equivalents
5,158
(2,027)
Net (decrease) increase in cash and cash equivalents
(28,058)
12,391
Cash and cash equivalents, beginning of period
364,683
113,811
Cash and cash equivalents, end of period
336,625
126,202
Cash received during the period:
Income taxes
0
0
Interest
3,234
1,090
Cash paid during the period:
Income taxes
1,954
365
Interest
8,623
5,958
Noncash investing and financing activities
Additions to property, plant and equipment
$ 52
$ 0
v3.26.1
Condensed Interim Consolidated Balance Sheets (Unaudited) - CAD ($)
$ in Thousands
Jun. 30, 2026
Mar. 31, 2026
Dec. 31, 2025
Current assets:
Cash and cash equivalents
$ 336,625
$ 364,683
Restricted short-term investments
5,058
5,046
Amounts receivable, net
42,588
36,289
Inventory
107,456
110,513
Prepaid expenses and other assets
14,634
12,935
Total current assets
506,361
529,466
Other investments
125,468
108,010
Property, plant and equipment
311,203
316,494
Intangible assets
88,476
92,411
Goodwill
55,685
55,685
Other assets
16,725
16,666
Total assets
1,103,918
1,118,732
Current liabilities:
Accounts payable
28,606
34,817
Other accrued expenses and liabilities
47,119
42,999
Current portion of long-term debt
28,824
16,237
Warrant derivative liability
26,863
27,522
Other liabilities
35,341
36,868
Total current liabilities
166,753
158,443
Long-term debt
211,379
217,123
Deferred income tax liabilities
7,915
8,199
Other liabilities
29,238
37,373
Total liabilities
415,285
421,138
Commitments and contingencies
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited; Issued and outstanding - 423,021,942 shares and 422,068,225 shares, respectively. Exchangeable shares - $nil par value; Authorized - unlimited; Issued and outstanding - 26,261,474 shares and 26,261,474 shares, respectively.
9,235,469
9,233,577
Additional paid-in capital
2,590,610
2,591,714
Accumulated other comprehensive income
15,360
10,530
Deficit
(11,152,806)
(11,138,227)
Total shareholders' equity
688,633
697,594
Total liabilities and shareholders' equity
$ 1,103,918
$ 1,118,732